News for 'natco-pharma'

US Fed rate hike boosts Sensex by 309 points; Nifty ends near 7,850

US Fed rate hike boosts Sensex by 309 points; Nifty ends near 7,850

Rediff.com17 Dec 2015

Index heavyweight RIL surged 3% to end above Rs 1,000 mark while IT majors were also the top gainers.

Best and worst performing stocks in 2015

Best and worst performing stocks in 2015

Rediff.com30 Nov 2015

Natco Pharma, Wockhardt and Marksans have rallied between 50 and 70 per cent in the year till date.

Markets at lifetime high; Nifty above 8K for first time

Markets at lifetime high; Nifty above 8K for first time

Rediff.com1 Sep 2014

The benchmark Nifty rallied 1,000 points or 17% from 7,000 in 78 trading sessions since May 12, till date to surpass the 8,000 mark.

US maintains status quo on India's patent regime

US maintains status quo on India's patent regime

Rediff.com1 May 2014

Special 301 Report expresses concern over weak IPR laws, to conduct reviews.

Sensex ends in red, Nifty at 2-week low; telecom shares rally

Sensex ends in red, Nifty at 2-week low; telecom shares rally

Rediff.com10 Mar 2015

Sensex ends 134.91 pts down at 28,709.87; Nifty falls 44.70 pts at 8,712.05.

Sensex rises, Nifty ends at record high; RIL shares rally

Sensex rises, Nifty ends at record high; RIL shares rally

Rediff.com3 Mar 2015

Sensex rises, Nifty ends at record high; RIL shares rally.

Sensex ends Samvat 2070 with 26% gain

Sensex ends Samvat 2070 with 26% gain

Rediff.com22 Oct 2014

The Nikkei share average rose 2.6% to close at 15,195.77 points, more than recouping Tuesday's losses.

Stocks you must buy, hold or exit

Stocks you must buy, hold or exit

Rediff.com25 Aug 2020

Ajit Mishra, vice president, Research, Religare Broking, answers your queries:

Markets extend losses for third straight day

Markets extend losses for third straight day

Rediff.com20 Jun 2014

Benchmark share indices ended lower for the third straight session as investors turned cautious amid tensions in Iraq even as consumer durables shares stole the limelight tracking rally in gold prices.

Pill for thought: Sweetheart deals that hurt consumers

Pill for thought: Sweetheart deals that hurt consumers

Rediff.com16 Sep 2014

'Pay-for-delay' settlements between drug patent-holders and generics manufacturers to delay the launch of cheaper generic medicine are increasingly being scrutinised by antitrust regulators

« Prev  |